Nanoform files for GMP certification
Nanoform has filed for GMP status with the Finnish Medicines Agency, FIMEA. The drug substance application for GMP clinical manufacture certification exemplifies its progress and growth in the last 12 months.
Nanoform wins the CPhI Excellence in Pharma Award for Formulation
Nanoform, an innovative medicine enabling nanotechnology company, has won the Excellence in Pharma Award for Formulation at the prestigious CPhI Pharma Awards.
Nanoform nominated for CPhI Award!
We are delighted to have been shortlisted as a finalist for the CPhI Award in the Excellence in Pharma: Formulation category.
Nanoform and AstraZeneca Initiate Technology Evaluation
Nanoform is delighted to announce the initiation of a technology evaluation of Nanoform’s Proprietary CESS Technology across a range of AstraZeneca’s proprietary pharmaceutical products.
Nanoform strengthens board with appointment of Mads Laustsen
Nanoform has appointed Mads Laustsen as a non-executive board member. This appointment will further strengthen the experienced Nanoform board and support the company as it increases its ability to deliver nanonized APIs for global partners across the pipeline from late stage drug discovery to commercial.
Nanoform appoints Mike Rea as Strategic Innovation Advisor
Nanoform has appointed Mike Rea as its Strategic Innovation Advisor. The role will involve working closely with Nanoform to maximise the value its proprietary nanonization technology can deliver to pharmaceutical partners and patients globally.
Nanoform appoints Director of Investor Relations following international growth
Nanoform has appointed Henri von Haartman as Director of Investor Relations. The newly created role will enrich investor relations as Nanoform seeks to further its shareholder base and continue its international growth, including expansion into the US market.
Nanoform continues strategic growth with €10 million private placement
Nanoform announced the completion of a private placement totaling €10 million, with Ilmarinen Mutual Pension Insurance Company and Mandatum Life Insurance Company (Sampo Group) acting as anchor investors.